HC Wainwright Issues Negative Outlook for KROS Earnings

Posted by on May 19th, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Keros Therapeutics in a note issued to investors on Friday, May 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($1.27) for the quarter, down from their prior estimate of ($0.91). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.93) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.33) EPS, FY2026 earnings at ($5.12) EPS, FY2027 earnings at ($5.88) EPS, FY2028 earnings at ($4.12) EPS, FY2029 earnings at ($2.41) EPS and FY2030 earnings at ($0.53) EPS.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The company had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%.

A number of other research firms have also recently commented on KROS. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday. Wells Fargo & Company dropped their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Finally, Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.40.

View Our Latest Stock Report on KROS

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.16 on Tuesday. The stock has a 50-day simple moving average of $11.41 and a two-hundred day simple moving average of $15.68. The firm has a market capitalization of $201.07 million, a P/E ratio of -3.38 and a beta of 0.95. Keros Therapeutics has a fifty-two week low of $10.07 and a fifty-two week high of $22.55.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC boosted its holdings in Keros Therapeutics by 1,420.6% in the 4th quarter. SG Americas Securities LLC now owns 98,703 shares of the company’s stock worth $2,010,000 after buying an additional 92,212 shares during the last quarter. Western Standard LLC boosted its holdings in Keros Therapeutics by 42.7% in the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after buying an additional 654,989 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Keros Therapeutics by 260.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 171,941 shares of the company’s stock worth $2,720,000 after buying an additional 124,287 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in Keros Therapeutics in the 4th quarter worth about $890,000. Finally, Cornerstone Investment Partners LLC acquired a new stake in Keros Therapeutics in the 3rd quarter worth about $176,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

(Get Free Report)

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

Read More

Earnings History and Estimates for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.